Puma Biotech's (PBYI) Neratinib Wins Backing From FDA Panel
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Up)Join SI Premium – FREE
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Puma Biotech's (NASDAQ: PBYI) Neratinib won backing from an FDA panel in a 12 to 4 vote supporting the drug's risk-benefit profile.
Trading remains halted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caladrius Biosciences (CLBS) to Resume Trading at 4:35 p.m. After Suspending Patient Enrollment in Phase 2b FREEDOM Trial of XOWNA
- Needham & Company Downgrades Verrica Pharmaceuticals (VRCA) to Hold, Removes Price Target on "Uncertain Delay", Reiterates that "Ycanth Has a Bright Commercial Future"
- Phathom Pharmaceuticals Inc. (PHAT) Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News, Trading HaltsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
